Lilly Says Bridge Program Boosts GLP-1 Sales and Supports Raised Guidance
Eli Lilly says its U.S. Bridge program is boosting sales of its GLP-1 drugs and was a key driver of its raised full-year revenue guidance. The program started in July.
Story updates
04:12:17 PM UTC
SquawkNews
Eli Lilly sees further runway ahead after getting a strong start with the Bridge program, a federal initiative that allows eligible Medicare beneficiaries to get insurance coverage for GLP-1 drugs like Lilly's Zepbound and Foundayo, as well as Novo Nordisk's Wegovy. "It's still early days," says Il…
Eli Lilly says the Bridge program is boosting sales of its GLP-1 drugs in the U.S., and a key driver behind its raised full-year revenue guidance. The program, which started in July, is a federal initiative that allows certain Medicare beneficiaries to get insurance coverage for FDA-approved GLP-1…